Global Expansion CordenPharma is actively expanding its manufacturing footprint with new facilities in Caponago, Italy and plans to add aseptic fill & finish lines, signaling increased capacity for injectables and high-potency vaccines. This creates opportunities to offer CDMO services for sterile, high-value products in Europe and beyond.

GLP-1 Capacity Significant investment in GLP-1 peptide production capacity demonstrates a strategic push into high-demand peptide therapeutics. Targeted outreach to clients developing GLP-1 or related peptide drugs could unlock collaboration on development, manufacturing, or scale-up.

US and China Footprint Recent facility expansions in the United States and China position CordenPharma to support global supply chains and regional manufacturing. This aligns with customers seeking multi-regional production, rapid transfer of programs, and risk diversification.

Lifecycle CDMO With six technology platforms including peptides, lipids & carbohydrates, oligonucleotides, injectables, highly potent & oncology, and small molecules, CordenPharma can shepherd projects across development to commercial manufacture, enabling seamless outsourcing for complex modalities.

Life Sciences Partnerships Strategic partnerships in education and workforce development in Colorado and ongoing industry collaborations indicate a commitment to expanding capability and talent pipelines. This can be leveraged to position CordenPharma as a partner for customers prioritizing scalable, trained manufacturing capacity and industry ecosystem support.